Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Granzyme b

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Granzyme b. Displaying page 1 of 1.
    EudraCT Number: 2010-023815-33 Sponsor Protocol Number: GHB_CSP_CL_00008_03 Start Date*: 2011-01-05
    Sponsor Name:AVIR Green Hills Biotechnology Research Development Trade AG
    Full Title: Randomised, double-blind, placebo-controlled, phase I/II study of single dose GHB16L2 trivalent influenza vaccine in healthy adults
    Medical condition: The intended indication for the IMP GHB16L2 is prevention of influenza A (H1N1, H3N2) and B contained in the vaccine.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015902-20 Sponsor Protocol Number: GHB-CS07 Start Date*: 2009-11-04
    Sponsor Name:AVIR Green Hills Biotechnology Research Development Trade AG
    Full Title: Randomized, double-blind, placebo-controlled, Phase IIa dose finding study of single dose GHB11L1 in healthy adults
    Medical condition: GHB-CS07 is a healthy volunteer trial. The intended indication for the investigational medicinal product (GHB11L1) is prevention of influenza A (H1N1).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003049-41 Sponsor Protocol Number: 50934 Start Date*: 2014-01-27
    Sponsor Name:National Institute of Child Health
    Full Title: A Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children
    Medical condition: Recurrant respiratory papillomatosis
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001515-22 Sponsor Protocol Number: S54226 Start Date*: 2012-05-16
    Sponsor Name:Katholieke Universiteit Leuven
    Full Title: Cytomegalovirus infection and the influenza vaccination response in older persons
    Medical condition: Humoral and cellular immune response after vaccination in older people
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018491-24 Sponsor Protocol Number: 31295 Start Date*: 2010-07-15
    Sponsor Name:Vrije Universiteit Medical Center
    Full Title: Effect of aminobisphosphonates and statins on circulating Vy9Vd2-T cells
    Medical condition: patients with malignant bone metastases
    Disease: Version SOC Term Classification Code Term Level
    12.1 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004429-15 Sponsor Protocol Number: GEM-1402 Start Date*: 2016-02-16
    Sponsor Name:GRUPO ESPAÑOL MULTICISPLINAR DE MELANOMA
    Full Title: Phase II multicente, non randomized, open label trial of nivolumab in combination with ipilimumab in subjects with previously untreated metastatic uveal melanoma.
    Medical condition: Metastatic uveal melanoma non suitable for radical resection.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000709-10 Sponsor Protocol Number: UKM12_0026 Start Date*: 2014-12-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005989-38 Sponsor Protocol Number: Start Date*: 2012-11-01
    Sponsor Name:Norwegian University of Science and Technology
    Full Title: A SAFETY AND EFFICACY STUDY OF ADDING LOW DOSE PEGYLATED IFN-ΑLPHA 2B TO STANDARD DOSE DASATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
    Medical condition: Chronic myeloid leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) FI (Completed) SE (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004321-25 Sponsor Protocol Number: NordDutchCML009 Start Date*: 2013-04-03
    Sponsor Name:VU University Medical Center
    Full Title: A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon α2b in patients with suboptimal molecular response or stable detectable molecular residual disease af...
    Medical condition: Chronic myeloid leukemia in chronic phase and ≥ 2 years on Imatinib treatment with suboptimal molecular response (BCR-ABL level above 0.01% IS).
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) SE (Completed) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005843-40 Sponsor Protocol Number: PXD101-CLN-19 Start Date*: 2008-11-11
    Sponsor Name:Spectrum Pharmaceuticals Inc.
    Full Title: A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Medical condition: Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004851 10034622 Peripheral T-cell lymphomas NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) DE (Completed) ES (Completed) HU (Completed) SK (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000440-22 Sponsor Protocol Number: EURO-SKI01 Start Date*: 2012-04-11
    Sponsor Name:University of Heidelberg
    Full Title: MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI
    Medical condition: Patients with chronic myeloid leukemia with complete molecular response can stop tyrosine kinase inhibitors under close monitoring
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10009016 Chronic myeloid leukemia in remission LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) FI (Completed) CZ (Completed) NL (Ongoing) NO (Completed) PT (Completed) AT (Prematurely Ended) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:23:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA